Tech Transfer eNews Blog

Columbia U inks licensing deal for “heart-on-a-chip” technology


By Jesse Schwartz
Published: May 29th, 2019

Columbia University has completed an exclusive, worldwide license agreement with New York City-based TARA Biosystems, Inc. (TARA), for intellectual property relating to engineered human heart tissues.

TARA is a company offers human “heart-on-a-chip” technology used for cardiac risk assessment and drug discovery. The licensed technology was developed at Columbia lab of Gordana Vunjak-Novakovic, PhD, a leading expert in engineering functional human tissues for regenerative medicine. Her work has been published in over 390 journal articles, with over 42,500 citations, making her one of the most highly cited individuals across all scientific and engineering disciplines.

Dr. Vunjak-Novakovic is a scientific co-founder of TARA Biosystems, along with her former trainee Dr. Milica Radisic, whose groundbreaking research is the foundation of the patented Biowire™ II platform. The Biowire™ II platform, for which TARA is the exclusive worldwide licensee, enables TARA’s market-leading solutions for cardiac risk assessment and drug discovery applications.

Dr. Vunjak-Novakovic commented, “I have great confidence in the TARA team and their ability to deliver on the promise of our intellectual property. We are inspired by the same mission to help improve the lives of patients and their families through safer and more effective therapies.”

“We are very pleased to enter into this exclusive license with TARA, which has been a core part of the rapidly growing NYC life sciences start-up ecosystem,” said Orin Herskowitz, executive director of Columbia Technology Ventures, the university’s tech transfer arm. “We are excited to be a part of TARA’s current and future success.”

Source: AccessWire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment